Extracellular vesicles for vaccine delivery
AssigneeLonza Sales AG
InventorsRaymond J. Moniz, Russell E. Mcconnell, Nikki Ross, Christine Mccoy, Timothy J. Soos, Ke Xu
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to extracellular vesicles (EVs), e.g., exosomes, comprising a payload (e.g., an antigen, adjuvant, and/or immune modulator) and/or a targeting moiety. Also provided herein are methods for producing the EVs (e.g., exosomes) and methods for using the EVs (e.g., exosomes) to treat and/or prevent diseases or disorders, e.g., cancer, graft-versus-host disease (GvHD), autoimmune disease, infectious diseases, or fibrotic diseases.
Claims19
An isolated extracellular vesicle (EV) comprising (i) an antigen, (ii) a first scaffold moiety, and (iii) an adjuvant,
- wherein the first scaffold moiety comprises a prostaglandin F2 receptor negative regulator (PTGFRN) protein or a fragment thereof.
An isolated extracellular vesicle (EV) comprising (i) an antigen, (ii) a first scaffold moiety and (iii) an immune modulator, wherein the first scaffold moiety comprises a prostaglandin F2 receptor negative regulator (PTGFRN) protein or a fragment thereof.
Dependencies are inferred from the claim text.